These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36038734)

  • 1. Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism.
    Hu M; Sun D; Yu J; Fu Y; Qin Z; Huang B; Zhang Q; Chen X; Wei Y; Zhu H; Wang Y; Feng Y; Zheng W; Liao H; Li J; Wu S; Zhang Z
    Lab Invest; 2022 Dec; 102(12):1335-1345. PubMed ID: 36038734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
    Wang Y; Wang Y; Zhang Z; Park JY; Guo D; Liao H; Yi X; Zheng Y; Zhang D; Chambers SK; Zheng W
    Oncotarget; 2016 Mar; 7(9):10363-72. PubMed ID: 26824415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression.
    Jiang Y; Chen X; Wei Y; Feng Y; Zheng W; Zhang Z
    Biomed Pharmacother; 2019 May; 113():108712. PubMed ID: 30849641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism.
    Bai M; Yang L; Liao H; Liang X; Xie B; Xiong J; Tao X; Chen X; Cheng Y; Chen X; Feng Y; Zhang Z; Zheng W
    Oncogene; 2018 Oct; 37(42):5666-5681. PubMed ID: 29921847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NrCAM secreted by endometrial stromal cells enhances the progestin sensitivity of endometrial cancer cells through epigenetic modulation of PRB.
    Cheng Y; Xie L; Xu Z; Hao M; Yang B; Shan W; Wang Y; Lv Q; Chen X
    Cancer Gene Ther; 2022 Oct; 29(10):1452-1462. PubMed ID: 35388173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
    Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
    Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
    Pant A; Lee II; Lu Z; Rueda BR; Schink J; Kim JJ
    PLoS One; 2012; 7(7):e41593. PubMed ID: 22911820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of ten-eleven translocation 1 (TET1) expression as a diagnostic and prognostic biomarker of endometrial carcinoma.
    Liu NT; Perng CL; Chou YC; Ko PS; Lin YJ; Lin YC; Chang CC; Wang YC; Shang HS; Chao TK
    PLoS One; 2021; 16(11):e0259330. PubMed ID: 34731191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer.
    Wang S; Pudney J; Song J; Mor G; Schwartz PE; Zheng W
    Gynecol Oncol; 2003 Feb; 88(2):108-17. PubMed ID: 12586588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review.
    Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
    Acta Obstet Gynecol Scand; 2019 Sep; 98(9):1086-1099. PubMed ID: 30793281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving response to progestin treatment of low-grade endometrial cancer.
    Baxter E; Brennan DJ; McAlpine JN; Mueller JJ; Amant F; van Gent MDJM; Huntsman DG; Coleman RL; Westin SN; Yates MS; Krakstad C; Quinn MA; Janda M; Obermair A
    Int J Gynecol Cancer; 2020 Nov; 30(11):1811-1823. PubMed ID: 32381512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.
    Rizner TL; Smuc T; Rupreht R; Sinkovec J; Penning TM
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):126-35. PubMed ID: 16338060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series.
    Zakhour M; Cohen JG; Gibson A; Walts AE; Karimian B; Baltayan A; Aoyama C; Garcia L; Dhaliwal SK; Elashoff D; Amneus M; Walsh C
    BJOG; 2017 Sep; 124(10):1576-1583. PubMed ID: 28128512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid Hormone Receptor β Knockdown Reduces Suppression of Progestins by Activating the mTOR Pathway in Endometrial Cancer Cells.
    Ren B; Zhou J; Hu Y; Zhong R; Lv Q; Xie S; Li G; Yang B; Chen X; Zhu Y
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA-seq and ATAC-seq analysis of CD163
    Wang L; Lv Q; Wu P; Luo S; Liu S; Chen X; Luo X
    Cancer Med; 2023 Mar; 12(5):5964-5978. PubMed ID: 36373483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance.
    Chen X; Zhang Z; Feng Y; Fadare O; Wang J; Ai Z; Jin H; Gu C; Zheng W
    Mod Pathol; 2009 May; 22(5):699-708. PubMed ID: 19287462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
    Chae-Kim J; Garg G; Gavrilova-Jordan L; Blake LE; Kim TT; Wu Q; Hayslip CC
    Int J Gynecol Cancer; 2021 Dec; 31(12):1499-1505. PubMed ID: 34785524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma.
    Zhou Q; Li W; Kong D; Liu Z; Shi Z; Ma X; Li Y; Jiang J
    Cancer Med; 2019 Aug; 8(9):4380-4388. PubMed ID: 31215145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
    Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.
    Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ
    Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.